πŸ‡ΊπŸ‡Έ FDA
Patent

US 12350262

Methods of treatment for cystic fibrosis

granted A61KA61K31/404A61K31/443

Quick answer

US patent 12350262 (Methods of treatment for cystic fibrosis) held by Vertex Pharmaceuticals Incorporated expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/404, A61K31/443, A61K31/4439, A61K31/47